Is Buying Cellular Biomedicine Group Inc (NASDAQ:CBMG), Having Lower Short Interest a Winning Strategy?

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Logo

Investors sentiment increased to 3 in 2018 Q2. Its up 0.40, from 2.6 in 2018Q1. It is positive, as 6 investors sold Cellular Biomedicine Group, Inc. shares while 2 reduced holdings. 15 funds opened positions while 9 raised stakes. 1.41 million shares or 105.26% more from 685,017 shares in 2018Q1 were reported.
Pennsylvania-based Vanguard has invested 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). American Inc holds 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) or 7,559 shares. Ny State Common Retirement Fund reported 0% stake. Tiaa Cref Inv Limited reported 0% stake. Schwab Charles Investment reported 0% of its portfolio in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Geode Cap Mgmt Limited Liability Co holds 92,023 shares or 0% of its portfolio. Comml Bank Of Montreal Can has 0% invested in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). The California-based California Pub Employees Retirement has invested 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). National Bank & Trust Of Ny Mellon Corporation holds 0% or 34,579 shares in its portfolio. Deutsche Natl Bank Ag has 0% invested in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) for 18,592 shares. Blackrock stated it has 588,852 shares or 0% of all its holdings. Morgan Stanley stated it has 0% of its portfolio in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Legal & General Gru Public Limited Company owns 1,728 shares. Dimensional Fund L P has 0% invested in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). National Bank & Trust Of America Corporation De reported 0% stake.

The stock of Cellular Biomedicine Group Inc (NASDAQ:CBMG) registered a decrease of 4.17% in short interest. CBMG’s total short interest was 694,600 shares in November as published by FINRA. Its down 4.17% from 724,800 shares, reported previously. With 25,200 shares average volume, it will take short sellers 28 days to cover their CBMG’s short positions. The short interest to Cellular Biomedicine Group Inc’s float is 7.24%.

The stock decreased 6.08% or $1.07 during the last trading session, reaching $16.53. About 21,897 shares traded. Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) has risen 83.78% since November 14, 2017 and is uptrending. It has outperformed by 68.16% the S&P500.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. The company has market cap of $304.09 million. It focuses on developing and marketing cell therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. It currently has negative earnings. The firm develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy.

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Ratings Coverage

Among 2 analysts covering Cellular Biomedicine Gr (NASDAQ:CBMG), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Cellular Biomedicine Gr had 2 analyst reports since June 15, 2018 according to SRatingsIntel. The stock of Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) has “Buy” rating given on Wednesday, October 3 by FBR Capital.

More recent Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) news were published by: which released: “Cellular Biomedicine Group Reports Third Quarter Financial Results and Recent Business Highlights” on November 06, 2018. Also published the news titled: “88 Biggest Movers From Yesterday” on November 08, 2018.‘s news article titled: “Cellular Biomedicine Group to Provide Company Cancer Immunotherapy Pipeline Update and Facility Tour for …” with publication date: October 25, 2018 was also an interesting one.

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.